glp-1/gip agonists GLP-1 & GIP | Obesity and Diabetes Management | Harrison's updates (22nd Ed.) EASD 2018: benefits of GIP/GLP-1

Description

Obesity-induced endoplasmic reticulum stress causes chronic inflammation in adipose tissue

Some patients may need to wait for generic GLP-1 medications, which eventually will arrive on the scene

These combined mechanisms underpin their efficacy for both weight reduction and cardiometabolic protection ( In recent years, the remarkable efficacy of tirzepatide, a dual GIP/GLP-1 receptor agonist, has emerged ( However, these benefits are accompanied by concerns about side effects, cost, long-term sustainability and, above all, the loss of lean mass, which may be mitigated by concurrent exercise ( Exercise and lifestyle interventions remain foundational for obesity and metabolic disease management, offering broad health benefits, but are often limited by adherence and modest long-term weight loss ( Recent randomized controlled trials and meta-analyses suggest that combining GLP-1RAs with exercise may yield additive or synergistic effects on weight loss and metabolic syndrome severity as well as on oxidative stress and inflammation

One important area we focus on is understanding GLP-1 and the medications that mimic its beneficial effects, such as Ozempic

We must not consider fat to be anything other than what it is: a dynamic endocrine tissue that has interplay with other organs/tissues and poses risk to health. Amy E